2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0653AS
    Levobupivacaine-d9 hydrochloride
    		Inhibitor
    Levobupivacaine-d9 ((S)-(–)-Bupivacaie-d9) hydrochloride is deuterium labeled Levobupivacaine hydrochloride (HY-B0653A). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
    Levobupivacaine-d<sub>9</sub> hydrochloride
  • HY-162246
    Nav1.8-IN-5
    		Inhibitor
    Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research.
    Nav1.8-IN-5
  • HY-114691
    R 59494
    		Inhibitor
    R 59494, an anti-ischemic compound, is a potent blocker of Na+ and Ca2+ uptake induced by veratridine intoxication.
    R 59494
  • HY-B0653
    Levobupivacaine
    		Inhibitor
    Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
    Levobupivacaine
  • HY-A0093S1
    Mexiletine-d3 hydrochloride
    		Inhibitor
    Mexiletine-d3 (hydrochloride) is deuterium labeled Mexiletine (hydrochloride). Mexiletine hydrochloride (KOE-1173 hydrochloride), a Class IB antianhythmic, is a non-selective voltage-gated sodium channel blocker[1][2].
    Mexiletine-d<sub>3</sub> hydrochloride
  • HY-107695
    Remacemide hydrochloride
    		Antagonist
    Remacemide hydrochloride (FPL 12924AA), a moderate inhibitor of the Na+ channel, is a weak uncompetitive NMDA receptor antagonist with IC50s of 68 μM and 76 μM for MK-801 binding and NMDA currents, respectively. Remacemide hydrochloride is an anticonvulsant agent.
    Remacemide hydrochloride
  • HY-158160
    LBA-3
    		Inhibitor
    LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC50 of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable.
    LBA-3
  • HY-B0495S4
    Lamotrigine-13C3
    		Inhibitor
    Lamotrigine-13C3 is the 13C-labeled Lamotrigine. Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al.
    Lamotrigine-<sup>13</sup>C<sub>3</sub>
  • HY-P11045
    JNJ63955918
    		Inhibitor
    JNJ63955918 is a potent, highly selective, blocked-state Nav1.7 blocking peptide with an IC50 of 8.0 nM. JNJ63955918 can be used in pain research.
    JNJ63955918
  • HY-110358A
    QAQ
    		Inhibitor
    QAQ dichloride dichloride, a photoswitchable voltage-gated Nav and Kv channels blocker, blocks channels in its trans form (of the azobenzene photoswitch), but not in its cis form. QAQ dichloride dichloride is membrane-impermeant and only infiltrates pain-sensing neurons that express endogenous import channels. QAQ dichloride dichloride acts as a light-sensitive analgesic and can be used for studying of signaling mechanisms in acute and chronic pain.
    QAQ
  • HY-118048
    NAV 26
    		Inhibitor 99.79%
    NAV 26 (compound 26) is a selective voltage-gated sodium channel Nav1.7 blocker with an IC50 of 0.37 μM. NAV 26 can be used for pain research.
    NAV 26
  • HY-149944
    Analgesic agent-2
    		Inhibitor
    Analgesic agent-2 is a selective and orally active NaV1.8 Channel inhibitor, with an IC50 of 50.18 nM in HEK293 cells stably expressing human NaV1.8 channel. Analgesic agent-2 has analgesic activity.
    Analgesic agent-2
  • HY-16923A
    Crobenetine hydrochloride
    		Inhibitor
    Crobenetine hydrochloride (BIII-890 hydrochloride) is the hydrochloride form of Crobenetine (HY-16923). Crobenetine hydrochloride is a selective inhibitor for Na+ channel. Crobenetine hydrochloride displaces 3HBTX from site 2 of the Na+ channel (IC50=49 nM) in rat brain synaptosomes, exhibits only low binding affinity for other receptors and ion channels. Crobenetine hydrochloride protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents.
    Crobenetine hydrochloride
  • HY-15082
    Irampanel
    		Antagonist
    Irampanel (BIIR 561) is an AMPA receptor and voltage-dependent sodium channel blocker. Irampanel inhibits kainate-induced currents in rat cortical neurons.
    Irampanel
  • HY-159094
    Nav1.8-IN-15
    		Inhibitor
    Nav1.8-IN-15 (compound 6) is a potent Nav1.8 inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain.
    Nav1.8-IN-15
  • HY-A0042S
    Rufinamide-d2
    		Inhibitor
    Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome.
    Rufinamide-d<sub>2</sub>
  • HY-108425A
    AMG8380
    		Antagonist
    AMG8380, an orally active and less active enantiomer of AMG8379, can serves as a negative control. AMG8380 inhibits human and mouse voltage-gated sodium channel NaV1.7 with IC50s of 0.907 and 0.387 μM, respectively. AMG8380 blocks Tetrodotoxin (TTX)-sensitive native channels with an IC50 of 2560 nM.
    AMG8380
  • HY-135412
    N-Methyl Duloxetine hydrochloride
    		Inhibitor
    N-Methyl Duloxetine hydrochloride is an analgesic. N-Methyl Duloxetine (hydrochloride) elicits both tonic and use-dependent block of neuronal Na+ channels.
    N-Methyl Duloxetine hydrochloride
  • HY-P5772
    Jingzhaotoxin-II
    		Inhibitor
    Jingzhaotoxin-II, a 32 amino acid residues including two acidic and two basic residues, is a neurotoxin. Jingzhaotoxin-II inhibits voltage-gated sodium channels (VGSC) that significantly slows rapid inactivation of TTX-resistant (TTX-R) VGSC on cardiac myocytes with the IC50 of 0.26 μM.
    Jingzhaotoxin-II
  • HY-139786
    Cofirasersen
    		Inhibitor
    Cofirasersen is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.
    Cofirasersen
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.